Concepedia

Stacey Versavel

SV

Statistics

Publications

2

Citations

160

H-Index

2

Active since

2022

Affiliations

Cerevel Therapeutics (United States)(Current)

Stacey Versavel is an author at Cerevel Therapeutics (United States) specializing in medicine, antipsychotic pharmacotherapy, and advocacy.

Publications per year

2022–2023

2

Publications

2

Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial

John H. Krystal, John M. Kane, Christoph U. Correll et al. · The Lancet · 2022 · 109 citations

Medicine, Pharmacology, Pharmacotherapy +13

Diversity, equity, and inclusion in clinical trials: A practical guide from the perspective of a trial sponsor

Stacey Versavel, Alicia Subasinghe, Kenasha Johnson et al. · Contemporary Clinical Trials · 2023 · 51 citations · Full text

Medicine, Health Policy, Advocacy +14

1–2 of 2